Actively Recruiting
National Prospective Registry Evaluating the Inspiron EVO Drug-Eluting Stent for Complex Coronary Lesions
Led by Scitech Produtos Medicos SA · Updated on 2026-10-02
2000
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the Inspiron17 EVO drug-eluting stent in treating complex coronary artery lesions in patients with symptomatic ischemic heart disease. This observational study focuses on real-world patients with lesions in native coronary arteries and restenotic lesions. The goal is to gather data on how well the device works and its safety profile in everyday clinical practice. Participants receive the Inspiron17 EVO stent through percutaneous coronary intervention PCI. This device has a reduced crimped profile to improve safety and ease of lesion crossing, with an optimized design for increased radial strength. The study includes up to 2,000 patients treated at multiple sites in Brazil, following their outcomes for up to 12 months after the procedure. During the study, demographic, procedural, and follow-up information will be collected from participants. Researchers will monitor device success during the initial procedure, acute clinical success within 24 hours, and major adverse cardiac events over 12 months. Additional assessments include rates of revascularization, stent thrombosis, cardiovascular mortality, and imaging measures like luminal loss and percent area stenosis at 6 months. Participants will be observed and data collected to understand the stents performance in real-world use.
CONDITIONS
Brief Title
Brazilian Prospective Registry of the Inspiron EVO Drug-Eluting Stent in Complex Coronary Lesions
Research Team
M
Marco Aurélio A Costa, MD, PhD
A
Ana Paula B Pellaquim, MSc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here